Fortress Biotech, INC 10-Q quarterly reports

Fortress Biotech Inc. reported a significant net income of $110.4 million for Q1 2026, largely due to a $158.9 million gain from the sale of a Priority Review Voucher.

Fortress Biotech reported a significant turnaround to net income in Q3 2025, driven by strategic asset monetizations and increased product revenue from its dermatology portfolio.

Fortress Biotech reported a significant increase in net income for Q2 2025, driven by the deconsolidation gain from the sale of Checkpoint Therapeutics to Sun Pharma, despite ongoing operating losses.

Fortress Biotech's Q1 2025 results show a slight revenue increase, driven by the launch of Emrosi, alongside a pending acquisition of Checkpoint Therapeutics by Sun Pharma.

Fortress Biotech's Q3 2024 results show a net loss of $12.9 million, impacted by decreased revenue and increased interest expenses, while the company paused preferred stock dividends.

Fortress Biotech's Q2 2024 results show a decrease in revenue and a net loss, alongside strategic moves including debt restructuring and a pause in preferred stock dividends.

Fortress Biotech's Q1 2024 results show a net loss of $15.4 million, with revenue driven by dermatology product sales and ongoing development of its biopharmaceutical pipeline.